Glimchek M 2mg/500mg Tablet is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The synergistic action of these agents provides effective glycemic control in patients inadequately managed by diet, exercise, and monotherapy. Glimchek M is typically prescribed when monotherapy with either agent is insufficient to achieve target glycemic levels. It is important to initiate therapy with appropriate lifestyle modifications, including diet and physical activity. Dosage should be individualized based on patient response and tolerability. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, primarily due to Metformin, and hypoglycemia related to Glimepiride. Caution is advised in patients with renal or hepatic impairment, and periodic monitoring of blood glucose and renal function is recommended. Glimchek M is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal dysfunction, or hypersensitivity to its components.